Artificial Intelligence in Mental Health

Epidemiological reports have highlighted mental illness as the leading causes of disability adjusted life years (DALYs) worldwide, with estimated global costs at nearly $2.5T with a projected increase to over $6T by 2030. Mental illness alone will account for more than half of the projected total economic burden from non-communicable diseases over the next two decades. Despite the burgeoning human, social and economic burden of mental illness, healthcare systems worldwide remain inadequately prepared, particularly in the heterogenous societies of Asia. This presentation focuses on recent technological advances and pilot studies around the application of machine learning and other domains of artificial intelligence in mental health – suggesting innovative digital health models for disease prevention, early intervention and management.

Lawrence Wee , Chief Data Scientist at Allianz Asia-Pacific

Dr. Lawrence Wee is a data science practitioner and innovator in the health sciences. He is currently Chief Data Scientist at Allianz Asia-Pacific where he directs the development of data-driven innovation platforms for the APAC markets. He works closely with the different stakeholders of the industry, co-creating solutions in the intersection of fintech, insurtech and healthtech. Prior to this role, he founded the healthcare and biomedical analytics laboratory at the Institute of Infocomm Research (I2R) in Singapore, and served as principal investigator for research initiatives encompassing genomics, precision medicine, digital health and health services. After the stint at I2R, he moved on to Zuellig Pharma where he took on the role of Chief Data Scientist.
Dr. Wee sits on the scientific advisory boards of several technology companies, and speaks regularly at conferences on artificial intelligence, digital technology and healthcare. He was previously the President of the Association for Medical and Bio-informatics Singapore (AMBIS), and the current vice-chair of the Chinese-American Pharmaceutical Society (CABS) Singapore chapter. He received his Ph.D. in Computational Biology and Machine Learning from the National University of Singapore.

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more